Ramnodigin

Ramnodigin

SCHEMBL1812161

C[C@@H]1O[C@@H](O[C@H]2CC[C@@]3(C)[C@H](CC[C@@H]4[C@@H]3CC[C@]3(C)[C@@H](C5=CC(=O)OC5)CC[C@]43O)C2)CC[C@H]1O

nearest known ligand 0.84

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATP1A1 P05023 12/20 0.84
ATP1B1 P05026 12/20 0.84
ATP1A3 P13637 12/20 0.84
ATP1B2 P14415 12/20 0.84
ATP1A2 P50993 12/20 0.84
ATP1B3 P54709 12/20 0.84
FXYD2 P54710 12/20 0.84
ATP1A4 Q13733 12/20 0.84
TP53 P04637 5/20 0.81
SMN1; SMN2 Q16637 4/20 0.81
LMNA P02545 4/20 0.81
NPC1 O15118 3/20 0.81
RAB9A P51151 3/20 0.81
STAT3 P40763 2/20 0.81
USP2 O75604 1/20 0.81
ABCB11 O95342 1/20 0.81
MAPT P10636 1/20 0.81
SLCO4C1 Q6ZQN7 1/20 0.81
HBB P68871 1/20 0.72
PAX8 Q06710 3/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ramnodigin SCHEMBL17861973 1.00 ATP1A1 (0.84) ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2
SCHEMBL13475189 0.96 ATP1A1 (0.88) ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2
SCHEMBL14772029 0.94 ATP1A1 (0.83) ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2
SCHEMBL17861996 0.93 ATP1A1 (0.81) ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2
SCHEMBL17862030 0.92 TP53 (0.82) ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2
SCHEMBL17862039 0.92 TP53 (0.82) ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2
SCHEMBL17863988 0.92 TP53 (0.82) ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2
Digitoxigenin Monodigitoxoside SCHEMBL13897300 0.92 ATP1A1 (1.00) ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2
Digitoxigenin Monodigitoxoside SCHEMBL13092978 0.92 ATP1A1 (1.00) ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2
Digitoxigenin Monodigitoxoside SCHEMBL31275966 0.92 ATP1A1 (1.00) ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 US claimed
US-20100226943-A1 SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL UNIVERSITY OF FLORIDA (US) 2010-09-09 US claimed
EP-1954244-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY Scidose, Llc (US) 2008-08-13 EP claimed
WO-2007061529-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY SCIDOSE LLC. (US) 2007-05-31 WO claimed
US-20070116729-A1 Lyophilization process and products obtained thereby SCIDOSE LLC 2007-05-24 US claimed
US-20220047505-A1 Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration STI PHARMA, LLC (US) 2022-02-17 US disclosed
US-10463611-B2 Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration STI PHARMA, LLC (US) 2019-11-05 US disclosed
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 US disclosed
US-20140154313-A1 Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration STI PHARMA, LLC (US) 2014-06-05 US disclosed
EP-2717860-A1 CONTROLLED ABSORPTION WATER-SOLUBLE PHARMACEUTICALLY ACTIVE ORGANIC COMPOUND FORMULATION FOR ONCE-DAILY ADMINISTRATION STI Pharma, LLC (US) 2014-04-16 EP disclosed
WO-2012170676-A1 CONTROLLED ABSORPTION WATER-SOLUBLE PHARMACEUTICALLY ACTIVE ORGANIC COMPOUND FORMULATION FOR ONCE-DAILY ADMINISTRATION STI PHARMA, LLC (US) 2012-12-13 WO disclosed
US-8158152-B2 Preparing lyophilizates, especially those free of undesired extra components such as mono- or disaccharides; dosage forms of a wide variety of over 2000 drugs, such as rapidly dissolving tablets SCIDOSE LLC (US) 2012-04-17 US disclosed
EP-1954244-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY Scidose, Llc (US) 2008-08-13 EP disclosed
WO-2007061529-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY SCIDOSE LLC. (US) 2007-05-31 WO disclosed
US-20070122474-A1 Pharmaceutical preparation comprising an active dispersed on a matrix ALTANA PHARMA AG 2007-05-31 US disclosed
US-20070116729-A1 Lyophilization process and products obtained thereby SCIDOSE LLC 2007-05-24 US disclosed
US-7175854-B2 Pharmaceutical preparation comprising an active dispersed on a matrix ALTANA PHARMA AG (DE) 2007-02-13 US disclosed
US-20040058896-A1 Pharmaceutical preparation comprising an active dispersed on a matrix ASTRAZENECA AB (SE) 2004-03-25 US disclosed
EP-1341527-A1 PHARMACEUTICAL PREPARATION COMPRISING AN ACTIVE DISPERSED ON A MATRIX ALTANA Pharma AG (DE) 2003-09-10 EP disclosed
WO-2002045693-A1 PHARMACEUTICAL PREPARATION COMPRISING AN ACTIVE DISPERSED ON A MATRIX ALTANA PHARMA AG (DE) 2002-06-13 WO disclosed